Skin repair composition, skin repair product and application of skin repair composition and skin repair product

Abstract

The invention provides a skin repair composition, a skin repair product and application of the skin repair composition and the skin repair product. The skin repair composition comprises the polydeoxyribonucleotide and the salt thereof, the Ectoine or the derivative thereof and the schizophyllan, overcomes the defect of single function of bioactive substances, and has the effects of inhibiting expression of inflammatory factors and accelerating repair of damaged skin pigmentation. The three active ingredients in the skin repair composition are not simply superposed, but generate a synergistic gain effect of '1 + 1 + 1gt, 3', the safety and effectiveness are obviously superior to those in the prior art, and a brand-new and excellent solution is provided for solving the problems of light and moderate acne of teenagers and hyperpigmentation after healing.

Description

Technical Field

[0001] This application relates to the field of skin repair technology, specifically to a skin repair composition, skin repair product, and its application. Background Technology

[0002] Acne is the most common chronic inflammatory skin disease of the pilosebaceous unit among adolescents. Mild to moderate acne mainly manifests as inflammatory papules and pustules. This disease not only affects the appearance of adolescents but also has a significant negative impact on their mental health and social life. Inflammation is the core pathological element of acne. The large number of inflammatory factors released during the inflammatory response (such as IL-1α, IL-6, and TNF-α) not only exacerbate the severity of skin lesions but are also the primary cause of post-inflammatory hyperpigmentation. Post-inflammatory hyperpigmentation manifests as dark or reddish-brown marks left after acne heals. These marks are long-lasting and difficult to completely eliminate with conventional methods, becoming a major sequela that troubles adolescent patients.

[0003] Currently, management strategies for mild to moderate acne and post-acne hyperpigmentation in adolescents mainly include: Topical medications, such as retinoids, benzoyl peroxide, and antibiotics (clindamycin), can inhibit Propionibacterium acnes and promote exfoliation to some extent, but they are generally highly irritating. Retinoic acid can easily lead to dry skin, peeling, and increased photosensitivity; benzoyl peroxide may cause burning sensations, contact dermatitis, and even disrupt the skin's microecological balance. These irritants can themselves exacerbate inflammation, thereby increasing the risk of acne and post-acne hyperpigmentation.

[0004] Chemical peels and physical therapies: glycolic acid and salicylic acid peels, and laser treatments. These methods are effective for existing acne and post-acne pigmentation, but they are invasive procedures. For teenagers whose skin barrier function may be fragile during puberty, these methods are highly irritating, have long recovery periods, are costly, and carry the risk of inducing a new round of inflammation and pigmentation, thus limiting their applicability.

[0005] Functional skincare products and whitening ingredients, such as niacinamide, vitamin C derivatives, and azelaic acid, are used to improve pigmentation. However, these ingredients are mostly single-function targeted, focusing either on inhibiting melanin production or on mild anti-inflammatory effects, and cannot simultaneously address both acne inflammation and post-acne pigmentation. Their effects are slow, and their ability to suppress acute inflammation is limited, making it difficult to fundamentally block the pathways leading to acne and post-acne pigmentation.

[0006] Therefore, there is an urgent need in the field to develop a novel composition specifically designed for the skin characteristics of adolescents. This composition should have the ability to strongly inhibit the expression of key inflammatory factors, severing the link between inflammation and pigmentation at its source. At the same time, it must also have high safety and soothing and repairing properties to meet the needs of adolescents for long-term use, effectively relieving inflammation of mild to moderate acne and preventing post-healing pigmentation. Summary of the Invention

[0007] In view of the problems existing in the prior art, this application provides a skin repair composition, a skin repair product and its application.

[0008] Specifically, this application relates to the following aspects: 1. A skin repair composition comprising: (1) At least one polydeoxyribonucleotide and its salt; (2) At least one ectoine or its derivative; (3) At least one schizotypalin.

[0009] 2. The skin repair composition according to item 1, wherein the mass ratio of the polydeoxyribonucleotide and its salt, ectoine or its derivative, and schistosome is (0.05~2.0):(0.05~2.5):(0.05-1.5), preferably (0.1~1.5):(0.1~2.0):(0.1-1.0).

[0010] 3. The skin repair composition according to item 1 or 2, wherein the mycotoxin has a triple helix structure consisting of a glucan backbone formed by β-(1-3)-glucosidic bonds and branched side chains formed by β-(1-6)-glucosidic bonds; Preferably, the molecular weight of the schistosome is 200,000 Da to 2,000,000 Da, more preferably 800,000 Da to 2,000,000 Da; Preferably, the branching degree of the schistosome is 0.25~0.40.

[0011] 4. The skin repair composition according to any one of items 1-3, wherein the polydeoxyribonucleotide and its salt have a molecular weight of 50,000 Da to 1,000,000 Da.

[0012] 5. The skin repair composition according to any one of items 1-4, wherein the ectoine derivative comprises hydroxyectoine.

[0013] 6. A skin repair product comprising the skin repair composition described in any one of items 1-5.

[0014] 7. The skin repair product according to item 6, wherein the content of the polydeoxyribonucleotide and its salt is 0.05~2.0 wt%, the content of ectoine or its derivative is 0.05~2.5 wt%, and the content of schistosome is 0.05~1.5 wt%.

[0015] 8. The skin repair product according to item 6 or 7, wherein the skin repair product further comprises active ingredients and / or excipients that can be added in the field of skin repair; Preferably, the active ingredients include whitening active ingredients, wrinkle-reducing active ingredients, moisturizing active ingredients, or anti-aging active ingredients; Preferably, the excipients include matrix components, emulsifiers, thickeners, emollients, pH adjusters, osmotic pressure adjusters, preservatives, and sensory modifiers.

[0016] 9. The skin repair product according to any one of claims 6-8, wherein the skin repair product comprises a skin repair liquid, a patch serum, or a skin spray.

[0017] 10. The use of the skin repair composition of any one of items 1-5 or the skin repair product of any one of items 6-9 in anti-inflammatory and post-acne pigmentation improvement; or in the preparation of articles for anti-inflammatory and post-acne pigmentation improvement.

[0018] Beneficial technical effects of this application The skin repair composition of this application includes three active ingredients: polydeoxyribonucleotides and their salts, ectoine or its derivatives, and schistosome. This overcomes the deficiency of single-function bioactive substances, enabling them to inhibit the expression of inflammatory factors and accelerate the repair of pigmentation in damaged skin.

[0019] The three active ingredients in the skin repair composition of this application are not simply added together, but produce a synergistic effect of "1+1+1>3". They are significantly superior to existing technologies in terms of safety and efficacy, and provide a new and excellent solution for solving mild to moderate acne in adolescents and their post-healing pigmentation problems. Detailed Implementation

[0020] The present application is further illustrated below with reference to embodiments. It should be understood that the embodiments are only used to further illustrate and explain the present application and are not intended to limit the present application.

[0021] Unless otherwise defined, technical and scientific terms used in this specification have the same meaning as commonly understood by one of ordinary skill in the art. While similar or identical methods and materials may be applied in experimental or practical applications, materials and methods are described herein. In case of conflict, the definitions included herein shall prevail. Furthermore, materials, methods, and examples are for illustrative purposes only and are not intended to be limiting. The present application is further described below with reference to specific embodiments, but is not intended to limit the scope of the application.

[0022] To address the problems existing in the prior art, this application provides a skin repair composition, comprising: (1) At least one polydeoxyribonucleotide and its salt; (2) At least one ectoine or its derivative; (3) At least one schizotypalin.

[0023] Polydeoxyribonucleotides and their salts are single- or double-stranded polymers composed of phosphate groups, deoxyribose groups, and four bases (adenine, guanine, thymine, and cytosine). Polydeoxyribonucleotides and their salts are typically derived from nucleic acid fragments from salmon testes or mammalian tissues, and can also be prepared using methods such as microbial fermentation. Upon contact with tissue, polydeoxyribonucleotides and their salts are cleaved into purine and pyrimidine deoxyribonucleotides by cell membrane enzymes. These deoxyribonucleotides and their salts stimulate endothelial cell migration and activate the proliferation of fibroblasts and other cell lines by acting on adenosine A2A receptors. Polydeoxyribonucleotides and their salts possess regenerative properties, stimulating wound healing by promoting angiogenesis and increasing fibroblast growth rates.

[0024] In some embodiments, the polydeoxyribonucleotides and their salts are nucleic acid substances extracted from salmon testes and can be prepared with reference to the method described in patent CN202511772748.8.

[0025] In some embodiments, the polydeoxyribonucleotide salt includes one or more of its sodium, magnesium, zinc, potassium, and calcium salts; preferably, it is a sodium salt.

[0026] In some embodiments, the polydeoxyribonucleotide and its salts comprise PDRN, wherein the PDRN is a polydeoxyribonucleotide and its salts with a molecular weight of less than or equal to 1 million Da.

[0027] In some embodiments, the molecular weight of the polydeoxyribonucleotide and its salt is 50,000 Da to 1,000,000 Da, for example, it can be 50,000 Da, 100,000 Da, 150,000 Da, 200,000 Da, 250,000 Da, 300,000 Da, 350,000 Da, 400,000 Da, 450,000 Da, 500,000 Da, 550,000 Da, 600,000 Da, 650,000 Da, 700,000 Da, 750,000 Da, 800,000 Da, 850,000 Da, 900,000 Da, 950,000 Da, 1,000,000 Da, and any value between these values.

[0028] In some embodiments, the molecular weight of the polydeoxyribonucleotide and its salt is 100,000 Da to 700,000 Da.

[0029] Ectoine, also known as halophilic bacteria extract, is a small-molecule cyclic amino acid derivative that can protect halophilic bacteria under extreme conditions of high temperature, high salt, and high ultraviolet radiation. The dense charge distribution on the surface of the ectoine molecule allows it to strengthen hydrogen bonding between water molecules through electrostatic interactions, promoting the formation of a "water complex" and achieving a moisturizing effect. This "water complex" formation can also stabilize proteins and reduce cell damage caused by electromagnetic radiation. Ectoine can also reduce the expression of pro-inflammatory and inflammatory factors, block inflammatory responses, and enhance cellular resilience. It can promote the expression of heat shock protein genes without thermal shock, thus protecting and repairing cells and tissues. Simultaneously, ectoine can inhibit melanin synthesis, exhibiting a certain whitening effect.

[0030] Derivatives of ectoine are known in the art, such as hydroxyectoine.

[0031] Schizophyllum hexandrin is a uniquely structured β-glucan secreted by *Schizophyllum commune*, possessing a triple helix structure consisting of a glucan backbone formed by β-(1-3)-glucosidic bonds and branched side chains formed by β-(1-6)-glucosidic bonds. This unique molecular configuration not only endows schizophyllum hexandrin with excellent water solubility, viscoelasticity, and biological stability, but also enables it to exhibit significant immunomodulatory, anti-inflammatory, and wound-healing-promoting biological activities. Furthermore, schizophyllum hexandrin can interfere with the adhesion process of *Propionibacterium acnes*. For *Propionibacterium acnes* to colonize the skin surface and cause inflammation, it first needs to adhere to skin cells. Schizophyllum hexandrin may bind to the surface of skin cells or to the adhesion structures of *Propionibacterium acnes*, preventing the adhesion of *Propionibacterium acnes*, thereby reducing its number on the skin surface and lowering the probability of acne occurrence.

[0032] In some embodiments, the backbone of the schistosome is a β-1-3-pyranose, with one of every three sugar saccharides linked to a β-1-6-pyranose, forming a triple helix structure, as shown below:

[0033] In some embodiments, the schizotypalin can be prepared by microbial fermentation, for example by fermentation of Schizophyllum commune.

[0034] In some implementations, wild strains of Schizophyllum commune are obtained through screening, and the fermentation broth containing schizophyllum commune is obtained through fermentation technology. Then, the schizophyllum commune powder product is obtained through purification, refining and other processes.

[0035] In some embodiments, the molecular weight of the schistosome is between 200,000 Da and 2,000,000 Da, for example, it can be 200,000 Da, 250,000 Da, 300,000 Da, 350,000 Da, 400,000 Da, 450,000 Da, 500,000 Da, 550,000 Da, 600,000 Da, 650,000 Da, 700,000 Da, 750,000 Da, 800,000 Da, 850,000 Da, 900,000 Da, 950,000 Da, 1,000,000 Da, 1,050,000 Da, 1,100,000 Da, 1,150,000 Da, 1,200,000 Da, 1,250,000 Da, 1,300,000 Da, 1,350,000 Da, 1,400,000 Da, 1,450,000 Da, 1,500,000 Da, 1,550,000 Da, 1,600,000 Da, 1,650,000 Da, 1,700,000 Da, 1,750,000 Da, 1,800,000 Da, 1,850,000 Da, 1,900,000 Da, 1,950,000 Da, 2,000,000 Da, and any value between these values.

[0036] In some embodiments, the molecular weight of the schistosome is 800,000 Da to 2,000,000 Da.

[0037] In some embodiments, the molecular weight of the schistosome is 1 million Da to 1.8 million Da.

[0038] In some embodiments, the branching degree of the mycotoxin is 0.25 to 0.40, for example, it can be 0.25, 0.26, 0.27, 0.28, 0.29, 0.30, 0.31, 0.32, 0.33, 0.34, 0.35, 0.36, 0.37, 0.38, 0.39, 0.40, and any value between these values.

[0039] In some embodiments, the branching degree of the mycotoxin is 0.30 to 0.35.

[0040] In some embodiments, the mass ratio of the polydeoxyribonucleotide and its salt, ectoine or its derivative, and schistosome is (0.05~2.0):(0.05~2.5):(0.05-1.5). Those skilled in the art will understand that 0.05~2.0 can be 0.05, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, and any value between these values; 0.05~2.5 can be 0.05, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 2.1, 2.2, 2.3, 2.4, 2.5, and any value between these values; 0.05-1.5 can be 0.05, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.1, 1.2, 1.3, 1.4, 1.5, and any value between these values.

[0041] In some embodiments, the mass ratio of the polydeoxyribonucleotide and its salt, ectoine or its derivative, and schizotypalin is (0.1~1.5):(0.1~2.0):(0.1-1.0).

[0042] In some embodiments, the skin repair composition comprises polydeoxyribonucleotides and their salts, ectoine or its derivatives, and schistosome, wherein the mass ratio of the polydeoxyribonucleotides and their salts, ectoine or its derivatives, and schistosome is (0.05~2.0):(0.05~2.5):(0.05-1.5), the polydeoxyribonucleotides and their salts have a molecular weight of 50,000 Da to 1,000,000 Da, and the schistosome is a triple helix structure consisting of a glucan backbone formed by β-(1-3)-glucan bonds and branched side chains formed by β-(1-6)-glucan bonds, with a molecular weight of 200,000 Da to 2,000,000 Da.

[0043] In some embodiments, the skin repair composition comprises polydeoxyribonucleotides and their salts, ectoine or its derivatives, and schizotypalin, wherein the mass ratio of the polydeoxyribonucleotides and their salts, ectoine or its derivatives, and schizotypalin is (0.1~1.5):(0.1~2.0):(0.1-1.0), the polydeoxyribonucleotides and their salts have a molecular weight of 100,000 Da to 700,000 Da, and the schizotypalin is a triple helix structure consisting of a glucan backbone formed by β-(1-3)-glucan bonds and branched side chains formed by β-(1-6)-glucan bonds, with a molecular weight of 800,000 Da to 2,000,000 Da.

[0044] This application also provides a skin repair product comprising the above-described skin repair composition.

[0045] Those skilled in the art will understand that the skin repair product may also include active ingredients and / or excipients that can be added in the field of skin repair.

[0046] In some embodiments, the active ingredients include whitening active ingredients, wrinkle-reducing active ingredients, moisturizing active ingredients, or anti-aging active ingredients, etc.

[0047] In some embodiments, the excipients include matrix components, emulsifiers, thickeners, emollients, pH adjusters, osmotic pressure regulators, preservatives, sensory modifiers, etc.

[0048] In some embodiments, the content of the polydeoxyribonucleotide and its salt in the skin repair product is 0.05 to 2.0 wt%, for example, it can be 0.05 wt%, 0.1 wt%, 0.2 wt%, 0.3 wt%, 0.4 wt%, 0.5 wt%, 0.6 wt%, 0.7 wt%, 0.8 wt%, 0.9 wt%, 1 wt%, 1.1 wt%, 1.2 wt%, 1.3 wt%, 1.4 wt%, 1.5 wt%, 1.6 wt%, 1.7 wt%, 1.8 wt%, 1.9 wt%, 2 wt%, and any value between these values.

[0049] The content of ectoine or its derivatives is 0.05~2.5 wt%, for example, it can be 0.05 wt%, 0.1 wt%, 0.2 wt%, 0.3 wt%, 0.4 wt%, 0.5 wt%, 0.6 wt%, 0.7 wt%, 0.8 wt%, 0.9 wt%, 1 wt%, 1.1 wt%, 1.2 wt%, 1.3 wt%, 1.4 wt%, 1.5 wt%, 1.6 wt%, 1.7 wt%, 1.8 wt%, 1.9 wt%, 2 wt%, and any value between these values.

[0050] The content of the mycotoxin is 0.05~1.5 wt%, for example, it can be 0.05 wt%, 0.1 wt%, 0.2 wt%, 0.3 wt%, 0.4 wt%, 0.5 wt%, 0.6 wt%, 0.7 wt%, 0.8 wt%, 0.9 wt%, 1 wt%, 1.1 wt%, 1.2 wt%, 1.3 wt%, 1.4 wt%, 1.5 wt%, and any value between these values.

[0051] In some embodiments, the content of the polydeoxyribonucleotide and its salt in the skin repair product is 0.1-1.5 wt%, the content of ectoine or its derivative is 0.1-2.0 wt%, and the content of schistosome is 0.1-1.0 wt%.

[0052] Skin repair products can refer to various types of skin repair products in this field, such as skin repair serums, sheet masks, and skin sprays.

[0053] This application also provides the use of the above-mentioned skin repair composition or skin repair product in anti-inflammatory and post-acne pigmentation improvement.

[0054] This application also provides the use of the above-described skin repair composition or skin repair product in the preparation of articles for anti-inflammatory purposes and for improving post-acne pigmentation.

[0055] This application's skin repair composition comprises three components: polydeoxyribonucleotides and their salts, ectoine or its derivatives, and schistosome extract. It overcomes the limitation of single-function bioactive substances, inhibiting the expression of inflammatory factors and accelerating the repair of pigmentation in damaged skin. Therefore, it can be used for anti-inflammatory purposes and to improve post-acne pigmentation. In particular, when polydeoxyribonucleotides and their salts, ectoine or its derivatives, and schistosome extract are present in a certain mass ratio, the three active ingredients can produce a synergistic effect, providing a novel and superior solution for addressing mild to moderate acne in adolescents and their post-healing pigmentation problems.

[0056] Example This application provides a general and / or specific description of the materials and test methods used in the experiments. In the following examples, unless otherwise specified, % represents wt%, i.e., weight percentage. All reagents or instruments used, unless otherwise specified, are commercially available conventional reagent products. Table 1 shows the sources of the raw materials used in the examples and comparative examples.

[0057] Table 1. Sources of raw materials used in the examples and comparative examples

[0058] Example 1: Preparation of Skin Repair Solution 1. Based on the total weight of the skin repair solution, 5.0 wt% butylene glycol, 3.0 wt% pentanediol and water for injection are thoroughly stirred and allowed to stand to obtain mixture A.

[0059] 2. Based on the total weight of the skin repair solution, add 0.1 wt% of schistosome (molecular weight 1.8 million Da, branching degree 0.30~0.35), 0.1 wt% of ectoine, and 0.1 wt% of sodium polydeoxyribonucleotide (molecular weight 690,000 Da) to the above mixture A, stir thoroughly for 6 h until homogeneous, and let stand to obtain a skin repair solution containing polydeoxyribonucleotide.

[0060] Example 2 The only difference between Example 2 and Example 1 is that, based on the total weight of the skin repair solution, the amount of mycotoxin is 1.0 wt%, and all other conditions are the same.

[0061] Example 3 The only difference between Example 3 and Example 1 is that, based on the total weight of the skin repair fluid, Ectocin is 2.0 wt%, while the other conditions are the same.

[0062] Example 4 The only difference between Example 4 and Example 1 is that, based on the total weight of the skin repair solution, the polydeoxyribonucleotide content is 1.5 wt%, while the other conditions are the same.

[0063] Example 5 1. Based on the total weight of the skin repair solution, 5.0 wt% butylene glycol, 3.0 wt% pentanediol and water for injection are thoroughly stirred and allowed to stand to obtain mixture A.

[0064] 2. Based on the total weight of the skin repair solution, add 0.5 wt% of schistosome (molecular weight 1.8 million Da, branching degree 0.30~0.35), 0.8 wt% of ectoine, and 0.5 wt% of sodium polydeoxyribonucleotide (molecular weight 690,000 Da) to the above mixture A, stir thoroughly for 6 h until homogeneous, and let stand to obtain a skin repair solution containing polydeoxyribonucleotide.

[0065] Example 6 The only difference between Example 6 and Example 5 is that the molecular weight of schizotypalin is 1 million Da, while the other conditions are the same.

[0066] Example 7 The only difference between Example 7 and Example 5 is that the molecular weight of the sodium polydeoxyribonucleotide is 186,000 Da, while the other conditions are the same.

[0067] Example 8 The only difference between Example 8 and Example 5 is that the molecular weight of schizotypalin is 200,000 Da, while the other conditions are the same.

[0068] Comparative Example 1 1. Based on the total weight of the skin repair solution, 5.0 wt% butylene glycol, 3.0 wt% pentanediol and water for injection are thoroughly stirred and allowed to stand to obtain mixture A.

[0069] 2. Based on the total weight of the skin repair solution, add 0.1 wt% of sodium polydeoxyribonucleotide (molecular weight 690,000 Da) to the above mixture A, stir thoroughly for 6 h until homogeneous, and let stand to obtain a skin repair solution containing sodium polydeoxyribonucleotide.

[0070] The difference between Comparative Examples 2 and 3 and Comparative Example 1 is that the amount of polydeoxyribonucleotide sodium salt added is 0.5 wt% and 1.5 wt%, respectively.

[0071] Comparative Example 4 1. Based on the total weight of the skin repair solution, 5.0 wt% butylene glycol, 3.0 wt% pentanediol and water for injection are thoroughly stirred and allowed to stand to obtain mixture A.

[0072] 2. Based on the total weight of the skin repair solution, add 0.1 wt% of ectoine to the above mixture A, stir thoroughly for 6 h until homogeneous, and let stand to obtain a skin repair solution containing ectoine.

[0073] The difference between Comparative Examples 5 and 6 and Comparative Example 2 is that the amount of ectoine added is 0.8 wt% and 2.0 wt%, respectively.

[0074] Comparative Example 7 1. Based on the total weight of the skin repair solution, 5.0 wt% butylene glycol, 3.0 wt% pentanediol and water for injection are thoroughly stirred and allowed to stand to obtain mixture A.

[0075] 2. Based on the total weight of the skin repair solution, add 0.1 wt% of myxobin (molecular weight 1.8 million Da, branching degree 0.30~0.35) to the above mixture A, stir thoroughly for 6 h until homogeneous, let stand, and obtain the skin repair solution containing myxobin.

[0076] The difference between Comparative Examples 8 and 9 and Comparative Example 1 is that the amount of schistosome added is 0.5 wt% and 1.0 wt%, respectively.

[0077] Comparative Example 10 1. Based on the total weight of the skin repair solution, 5.0 wt% butylene glycol, 3.0 wt% pentanediol and water for injection are thoroughly stirred and allowed to stand to obtain mixture A.

[0078] 2. Based on the total weight of the skin repair solution, add 0.5 wt% of myxobin (molecular weight 200,000 Da, branching degree 0.30~0.35) to the above mixture A, stir thoroughly for 6 h until homogeneous, let stand, and obtain the skin repair solution containing myxobin.

[0079] Comparative Example 11 The only difference between Comparative Example 11 and Comparative Example 2 is that the molecular weight of the sodium polydeoxyribonucleotide is 186,000 Da, while the other conditions are the same.

[0080] Blank control Based on the total weight of the skin repair solution, 5.0 wt% butylene glycol, 3.0 wt% pentanediol and water for injection were thoroughly stirred to obtain a blank control sample.

[0081] Specifically, the main parameters in the above embodiments and comparative examples are shown in Table 2.

[0082] Table 2

[0083] Test Example 1: Anti-inflammatory Test To determine the anti-inflammatory effects of the compositions of different Examples 1-8 and Comparative Examples 1-11 and the blank control, mouse macrophages Raw264.7 were used as model cells. They were stimulated with LPS to induce excessive secretion of pro-inflammatory cytokines. The cells were treated with samples prepared in Examples 1-8 and Comparative Examples 1-11. The contents of inflammatory factors interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) in the culture supernatant were quantitatively detected by ELISA to investigate the inhibitory effect of the samples on the release of inflammatory factors.

[0084] Model group: LPS-only culture medium Experimental group: Samples prepared in Examples 1-8 or Comparative Examples 1-11 + LPS culture medium Blank control group: Samples prepared as a blank control + LPS culture medium Inflammatory factor expression rate (%) = (average inflammatory factor content in the experimental group - average inflammatory factor content in the blank control group) / average inflammatory factor content in the model group × 100.

[0085] Inflammatory factor inhibition rate (%) = 100% - Inflammatory factor expression rate (%).

[0086] The results of the inhibition rates of inflammatory factors in each embodiment and comparative example are shown in Table 3.

[0087] Table 3. Effects of the compositions of each example and comparative example on the inhibition rate of inflammatory factors.

[0088] The results above show that higher inhibition rates of IL-6 and TNF-α indicate better inhibition of inflammatory factor expression and a better anti-inflammatory effect of the composition. In comparison, the anti-inflammatory effects of each embodiment are superior to those of the comparative examples. In particular, the anti-inflammatory effects of Examples 1-7 are superior to the simple sum of the individual anti-inflammatory effects of the three components. This indicates that the schistosome extract, polydeoxyribonucleotides and their salts, and ectoine in the skin repair composition prepared according to this application have a certain synergistic effect in inhibiting the expression of anti-inflammatory factors, effectively inhibiting the expression of IL-6 and TNF-α, thereby alleviating the level of skin inflammation caused by acne.

[0089] To further verify the synergistic effect among the components, we used the COLBY formula in Examples 1-5 as examples: E 理论 The formula is: =X+Y+Z-(XY+XZ+YZ) / 100+XYZ / 10000, which is used for verification, where X, Y, and Z are the IL-6 inhibition rate or TNF-α inhibition rate of single component treatment, respectively, and E... 理论 E represents the theoretical IL-6 inhibition rate or TNF-α inhibition rate after treatment with the composition. 实际 The inhibition rate of IL-6 or TNF-α after treatment with the composition; E 实际 >E 理论 To improve efficiency; E 实际 <E 理论 For antagonism; E 实际 =E 理论 For addition.

[0090] Among them, E in Example 1 理论 E was calculated from the data of Comparative Examples 1, 4, and 7 in Example 2. 理论 E was calculated from the data of Comparative Examples 1, 4, and 9 in Example 3. 理论 E was calculated from the data of Comparative Examples 1, 6, and 7 in Example 4. 理论 The E value of Example 5 was calculated from the data of Comparative Examples 3, 4, and 7. 理论 It was calculated from the data of comparative examples 2, 5, and 8.

[0091] The results of the synergistic effect determination are shown in Table 4.

[0092] Table 4

[0093] The results showed that E in Examples 1-5 实际 All are greater than E 理论 This indicates that the polydeoxyribonucleotides, schistocin, and ectoine in the composition have a synergistic anti-inflammatory effect.

[0094] Experimental Example 2: Acne Pigmentation Repair Experiment To verify the repair effect and user experience of this application on mild to moderate facial acne pigmentation, the applicant conducted a systematic trial observation on a small group of people, as detailed below: Trial subjects: 60 people with mild to moderate facial acne and pigmentation were randomly divided into 3 groups and tried the skin repair solutions prepared in each example and comparative example, as well as the blank control sample.

[0095] Dosage and administration: 1 mL twice a day for 30 days.

[0096] Skin brightness (L value) was measured using a skin tone analyzer (Minolta CD-2600 spectrophotometer, Japan). The L values ​​of the subjects' faces were recorded before and 30 days after sample use. The average L value for each group was taken, and the L value improvement rate was calculated using the following formula: L-value improvement rate = (L-value) （使用30天） -L value （使用前） ) / L value （使用前） ×100% The larger the L value, the lighter the color of acne pigmentation; the smaller the L value, the darker the color of acne pigmentation. A higher L value improvement rate indicates a better repair effect on acne pigmentation. The L value and L value improvement rate were used to detect the repair effect of the composition on acne pigmentation.

[0097] The test results are shown in Table 5.

[0098] Table 5. Feedback Table on the Effect of Each Example and Comparative Example Composition on Acne Pigmentation Repair in Individual Populations

[0099] As shown in Table 5, the L-values ​​and L-value improvement rates of the subjects in Examples 1-8 all showed significant increases after 30 days of continuous use of the samples, with improvement rates far exceeding those of the comparative proportions. This indicates that the repair composition of this application has a good repairing effect on acne pigmentation. In particular, the L-value improvement rate of Examples 1-7 was better than the simple sum of the L-value improvement rates of the three components individually, indicating that when schistosome extract, polydeoxyribonucleotides and their salts, and ectoine are used together, they have a synergistic effect, significantly reducing the pigmentation of the subjects' skin and effectively promoting the repair of acne-prone skin.

Claims

1. A skin repair composition comprising: (1) At least one polydeoxyribonucleotide and its salt; (2) At least one ectoine or its derivative; (3) At least one schizotypalin.

2. The skin repair composition according to claim 1, wherein, The mass ratio of the polydeoxyribonucleotide and its salt, ectoine or its derivative, and schistosome is (0.05~2.0):(0.05~2.5):(0.05-1.5), preferably (0.1~1.5):(0.1~2.0):(0.1-1.0).

3. The skin repair composition according to claim 1 or 2, wherein, The schizotypalin has a triple helix structure consisting of a glucan backbone formed by β-(1-3)-glucosidic bonds and branched side chains formed by β-(1-6)-glucosidic bonds. Preferably, the molecular weight of the schistosome is 200,000 Da to 2,000,000 Da; more preferably, it is 800,000 Da to 2,000,000 Da. Preferably, the branching degree of the schistosome is 0.25~0.

40.

4. The skin repair composition according to any one of claims 1-3, wherein, The molecular weight of the polydeoxyribonucleotides and their salts is 50,000 Da to 1,000,000 Da.

5. The skin repair composition according to any one of claims 1-4, wherein, The ectoine derivatives include hydroxyectoine.

6. A skin repair product comprising the skin repair composition according to any one of claims 1-5.

7. The skin repair product according to claim 6, wherein, In the skin repair product, the content of the polydeoxyribonucleotide and its salt is 0.05~2.0 wt%; the content of ectoine or its derivative is 0.05~2.5 wt%; and the content of schistosome is 0.05~1.5 wt%.

8. The skin repair product according to claim 6 or 7, wherein, The skin repair products also include active ingredients and / or excipients that can be added in the field of skin repair; Preferably, the active ingredients include whitening active ingredients, wrinkle-reducing active ingredients, moisturizing active ingredients, or anti-aging active ingredients; Preferably, the excipients include matrix components, emulsifiers, thickeners, emollients, pH adjusters, osmotic pressure adjusters, preservatives, and sensory modifiers.

9. The skin repair product according to any one of claims 6-8, wherein, The skin repair products include skin repair serums, sheet masks, or skin sprays.

10. The use of the skin repair composition of any one of claims 1-5 or the skin repair product of any one of claims 6-9 in anti-inflammatory and post-acne pigmentation improvement; or in the preparation of articles for anti-inflammatory and post-acne pigmentation improvement.

Images